BNTC - NASDAQ
Benitec Biopharma Inc.
$10.70
+1.1%Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
At a Glance
Live SnapshotBenitec Biopharma Inc. Profit Bridge
Profitability Analysis
Benitec Biopharma Inc. Income Statement
BNTC • NASDAQ
| Benitec Biopharma Inc. Income Statement | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||
0.0 | 0.0 | 75K | 73K | 59K | 97K | 11.3M | 455.4K | 450.3K | 346.5K | 829.1K | 1M | 545.7K | |
GROSS PROFIT | |||||||||||||
(396K) | (343K) | (381K) | (9K) | (123K) | (268.1K) | (426.5K) | (331.3K) | (209K) | (103.8K) | (30.7K) | (37.7K) | (176.1K) | |
-396K | -343K | -306K | 64K | -64K | -171.1K | 10.9M | 124.1K | 241.3K | 242.7K | 798.4K | 980.1K | 369.6K | |
OPERATING INCOME | |||||||||||||
(41.4M) | (22.3M) | (18.8M) | (17.9M) | (13.5M) | (8.6M) | (9M) | (8.7M) | (4.4M) | (16.2M) | (8.8M) | (11.3M) | (7.1M) | |
(23.4M) | (6.6M) | (6M) | (6.6M) | (6.5M) | (5.6M) | (6.7M) | (6.4M) | (7M) | (9M) | (6.2M) | (7.7M) | (4.4M) | |
(18.3M) | (15.6M) | (12.8M) | (11.3M) | (7M) | (3M) | (2.2M) | (5.1M) | (5.3M) | (9.9M) | (4.8M) | (5.9M) | (3.4M) | |
-41.8M | -22.6M | -19.1M | -17.9M | -13.6M | -8.3M | 2M | -8.6M | -15.9M | -25M | -13.3M | -14.4M | -8.2M | |
PRE-TAX INCOME | |||||||||||||
(0.0) | (0.0) | (33K) | (32K) | (6K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
3.3M | 904K | -33K | -32K | -6K | 62K | 122K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-396K | (0.0) | (0.0) | (0.0) | (0.0) | -5K | (154.8K) | (734.0) | -7.9M | -2.7M | -2.1M | -2.2M | -708.2K | |
3.8M | 847K | -481K | -354K | -286K | 7K | 606K | 179.2K | 11.6M | 6.5M | 4.5M | 3.6M | 1.3M | |
-37.9M | -21.8M | -19.6M | -18.2M | -13.9M | -8.3M | 2.9M | -8.6M | -4.4M | -18.5M | -8.8M | -10.8M | -6.8M | |
NET INCOME | |||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (27K) | -864.2K | (1.5K) | (0.0) | (0.0) | (0.0) | (0.0) | -414.3K | |
-37.9M | -21.8M | -19.6M | -18.2M | -13.9M | -8.3M | 2.9M | -8.6M | -4.4M | -18.5M | -8.8M | -10.8M | -6.4M |
SEC Filings
BNTC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 22, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | March 20, 2026 | June 30, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 12, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | January 30, 2026 | January 30, 2026 | ||
8-K 8-K 2025 N/A | December 02, 2025 | December 01, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 14, 2025 | 2025 |
Related Guides
Continue your BNTC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.